• Based on current screening and enrollment rates, topline data anticipated inearly Q2 2027
• Additional participants continue to roll over into the active extension arm of the trial
• COYA 302 has received FDA Fast Track designation for the treatment of ALS

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.